King's College London

Research portal

Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations

Research output: Contribution to journalArticlepeer-review

Sameer Jauhar, Serena Lai, Ilaria Bonoldi, Gonzalo Salazar de Pablo, Marta di Forti, Luis Alameda, Jacek Donocik, Eduardo Iacoponi, Thomas Spencer, Beate Haege, D McLaughlin, David Taylor, Allan H Young, Graham Thornicroft, Fiona Gaughran, James H MacCabe, Robin M Murray, Philip McGuire, Paolo Fusar-Poli

Original languageEnglish
JournalEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Early online date25 Feb 2021
DOIs
Accepted/In press9 Feb 2021
E-pub ahead of print25 Feb 2021

Bibliographical note

Funding Information: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. General sources of potential conflict of interest, considered unrelated to this work include the following: PFP has been a consultant to or has received honoraria or grants from Lundbeck, Menarini, Angelini, Boehringer Ingelheim. FG has received honoraria from Lundbeck, Otsuka, and Sunovion, and has a family member with professional links to Lilly and GSK, including shares. GSP is supported by the Alicia Koplowitz Foundation. FG is in part supported by the National Institute for Health Research's (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, the Stanley Medical Research Institute, the Maudsley Charity and the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. SJ has received speaker honoraria for educational talks given for Suonvian, and KCL has received honoraria for educational talks SJ has given for Lundbeck. AHY has received paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma Consultant to Johnson & Johnson Consultant to Livanova; he has received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. He has been principal Investigator in the Restore-Life VNS registry study funded by LivaNova. JM has received research funding from H Lundbeck and hospitality from H Lundbeck and Saladax Biochemicals. GT is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration South London at King's College London NHS Foundation Trust, and by the NIHR Asset Global Health Unit award. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. GT also receives support from the National Institute of Mental Health of the National Institutes of Health under award number R01MH100470 (Cobalt study). GT is supported by the UK Medical Research Council in relation the Emilia (MR/S001255/1) and Indigo Partnership (MR/R023697/1) awards . Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Documents

King's Authors

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454